



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Efruxifermin

Cat. No.:	HY-P99930
CAS No.:	2375240-92-7
Target:	FGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis ^[1] .								
IC ₅₀ & Target	FGF21								
In Vivo	<p>Efruxifermin (0-100 mg/kg, SC, Once weekly, for 4 or 26 weeks) reduces body weight gain of Sprague Dawley rats in a dose-dependent manner^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table><tr><td>Animal Model:</td><td>Male and female Sprague Dawley rats^[1]</td></tr><tr><td>Dosage:</td><td>0, 1, 10, 30, 100 mg/kg</td></tr><tr><td>Administration:</td><td>Subcutaneous injection, Once weekly, for 4 or 26 weeks</td></tr><tr><td>Result:</td><td>Significantly reduced body weight gain after 4 and 26 weeks, despite increasing food intake. Markers of sympathetic activation, urinary corticosterone and ratio of adrenal-to-body weight were unchanged.</td></tr></table>	Animal Model:	Male and female Sprague Dawley rats ^[1]	Dosage:	0, 1, 10, 30, 100 mg/kg	Administration:	Subcutaneous injection, Once weekly, for 4 or 26 weeks	Result:	Significantly reduced body weight gain after 4 and 26 weeks, despite increasing food intake. Markers of sympathetic activation, urinary corticosterone and ratio of adrenal-to-body weight were unchanged.
Animal Model:	Male and female Sprague Dawley rats ^[1]								
Dosage:	0, 1, 10, 30, 100 mg/kg								
Administration:	Subcutaneous injection, Once weekly, for 4 or 26 weeks								
Result:	Significantly reduced body weight gain after 4 and 26 weeks, despite increasing food intake. Markers of sympathetic activation, urinary corticosterone and ratio of adrenal-to-body weight were unchanged.								

REFERENCES

[1]. Tillman EJ, et al. Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats. *Br J Pharmacol.* 2022 Apr;179(7):1384-1394.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA